iPSC-derived cardiomyocytes from patients with peripartum cardiomyopathy with a MYBPC3 variant reveal calcium handling defects exacerbated under peripartum stress

J. H. Müller (Hannover)1, P. Baskin (Haifa)2, G. Göhring (Hannover)3, Y. L. Behrens (Hannover)3, M. Scherr (Hannover)4, T. Pfeffer (Hannover)5, J. Bauersachs (Hannover)1, D. Hilfiker-Kleiner (Hannover)6, O. Binah (Haifa)2, M. Ricke-Hoch (Hannover)5
1Medizinische Hochschule Hannover Kardiologie und Angiologie Hannover, Deutschland; 2Technion – Israel Institute of Technology Department of Physiology, Biophysics and System Biology, Ruth & Bruce Rappaport Faculty of Medicine and Research Institute Haifa, Israel; 3Medizinische Hochschule Hannover Humangenetik Hannover, Deutschland; 4Medizinische Hochschule Hannover Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Hannover, Deutschland; 5Medizinische Hochschule Hannover Klinik für Kardiologie und Angiologie Hannover, Deutschland; 6Medizinische Hochschule Hannover Präsidium Hannover, Deutschland

Background: Peripartum cardiomyopathy (PPCM) is a heart failure caused by left ventricular (LV) systolic dysfunction in late pregnancy, during delivery or early postpartum in previously heart-healthy women. Although 15-20% of PPCM patients carry variants in cardiomyopathy-related genes, their contribution to disease development remains unclear. Whole exome sequencing of 94 PPCM patients identified two sisters (S1, S2) with a heterozygous Myosin-binding protein C3 variant (MYBPC3, c.3052G>C;p.(Glu1018Gln), ACMG class 3) inherited from their asymptomatic father (F). S1 showed a mild PPCM (LV ejection fraction (LVEF) 45%), whereas S2 developed a severe PPCM (LVEF 17%) and additionally carries a de novo heterozygous Titin variant (TTN, c.44988del;p.(His14997Metfs*24), ACMG class 4). Mother (M) and brother (B) of the sisters carry neither variant and are heart-healthy. Since these patients were asymptomatic before pregnancy, peripartum (patho-)physiology in mutation carriers likely triggers heart failure.

Methods and results: Induced pluripotent stem cells (iPSCs) were generated from S1, F, B and M. An isogenic S1 control (S1-Ctrl) was created via CRISPR/Cas9 correction of the MYBPC3 variant. All iPSC lines showed normal karyotypes, common pluripotency markers and the ability of trilineage differentiation.
Ca2+ transient experiments under basal conditions in S1 and F iPSC-cardiomyocytes (CMs) revealed reduced caffeine-induced Ca2+ release from the sarcoplasmic reticulum (SR), and a shorter recovery time than in S1-Ctrl and M. Under 48 h estradiol (E2) treatment as peripartum-associated stressor, S1 and F iPSC-CMs also showed a reduction in the caffeine-induced Ca2+ release parameters compared to S1-Ctrl and M, which was further decreased under combined treatment of cyclic stretch (1 Hz) and E2 for 48 h. Combined stress also resulted in a shorter time to the first Ca2+ transient.
RNA sequencing of iPSC-CMs under E2 treatment and with or without stretch showed an altered expression of contractility-related genes in S1 versus S1-Ctrl iPSC-CMs. Under combined stretch and E2, the expression of ATP2A2 was 2.2-fold and RYR2 3.1-fold higher in S1 than in S1-Ctrl cells, suggesting an insufficient compensation for the MYBPC3 variant. Further, under combined stretch and E2, S1 cells had a 2.4-fold higher expression of ATP2A2 than stretch, which was not seen in S1-Ctrl cells, indicating a stress-dependent transcriptional dysregulation in S1 cells.

Conclusions: We generated patient-specific PPCM-iPSCs carrying a heterozygous MYBPC3 gene variant and corresponding controls. S1 and F iPSC-CMs show reduced SR Ca2+ release in response to caffeine compared with control iPSC-CMs, suggesting impaired Ca2+ handling and contractility of the iPSC-CMs by the MYBPC3 variant, exacerbating under peripartum-associated stress, potentially leading to cardiomyocyte dysfunction, which may contribute to PPCM. Consistent with the functional defects, RNA sequencing demonstrated stress-dependent dysregulation of contractility genes in S1 iPSC-CMs, indicating an insufficient transcriptional compensation for the MYBPC3 variant.